TENAX THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
TENX$1.69-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net Loss | $(7,710,673) | $(11,047,895) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 7,570 | 5,143 |
| Interest on debt instrument | 23,967 | 4,443 |
| Amortization of right of use asset | - | 108,189 |
| (Gain)/Loss on sale of equipment | 1,125 | (2,901) |
| Issuance and vesting of compensatory stock options and warrants | 190,850 | 365,314 |
| Changes in operating assets and liabilities | ||
| Accounts receivable, prepaid expenses and other assets | (305,694) | (356,520) |
| Accounts payable and accrued liabilities | 1,889,323 | (344,951) |
| Long term portion of lease liability | - | (119,393) |
| Net cash used in operating activities | (5,903,532) | (11,388,571) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Proceeds from sale/(purchase) of property and equipment | 2,843 | (2,323) |
| Net cash (used in) provided by investing activities | 2,843 | (2,323) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of warrants and pre-funded warrants, net of issuance costs | 14,192,278 | 7,928,591 |
| Proceeds from the exercise of warrants | 1,161 | 2,063 |
| Payments on short-term note | (624,302) | - |
| Net cash provided by financing activities | 13,569,137 | 7,930,654 |
| Net change in cash and cash equivalents | 7,668,448 | (3,460,240) |
| Cash and cash equivalents, beginning of period | 2,123,682 | 5,583,922 |
| Cash and cash equivalents, end of period | $9,792,130 | $2,123,682 |
| Non-cash operating activity | ||
| Addition to prepaids for insurance premium | $(500,903) | $(624,302) |
| Non-cash financing activity | ||
| Addition to notes payable for financing insurance premium | $500,903 | $624,302 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.